Trial Profile
A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2019
Price :
$35
*
At a glance
- Drugs Olopatadine (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Alcon
- 28 Nov 2015 New trial record